{"id":"foradil-p-12-g","safety":{"boxedWarning":"Long-acting beta-2 adrenergic agonists may increase the risk of asthma-related death. LABAs should not be used as monotherapy for asthma and should only be used in combination with an inhaled corticosteroid.","commonSideEffects":["Tremor","Headache","Palpitations","Muscle cramps","Nervousness"],"contraindications":["Hypersensitivity to formoterol or any component of the formulation"]},"_chembl":{"chemblId":"CHEMBL6049966","moleculeType":null,"molecularWeight":"541.01"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Beta-2 adrenergic receptor","explanation":"Formoterol binds to beta-2 adrenergic receptors on bronchial smooth muscle cells, stimulating adenylyl cyclase and increasing intracellular cyclic AMP levels. This leads to relaxation of bronchial smooth muscle and bronchodilation, with effects lasting up to 12 hours.","oneSentence":"Formoterol selectively activates beta-2 adrenergic receptors in airway smooth muscle, causing bronchodilation and improved airflow."},"_scrapedAt":"2026-03-28T03:32:35.846Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123861,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"Salmeterol","brand":"Serevent","company":"GlaxoSmithKline","rationale":"Long-acting beta-2 agonist for asthma and COPD maintenance therapy"},{"name":"Indacaterol","brand":"Onbrez","company":"Novartis","rationale":"Once-daily LABA for COPD with longer duration of action"},{"name":"Vilanterol","brand":"Breo Ellipta","company":"GlaxoSmithKline","rationale":"Ultra-long-acting beta-2 agonist used in combination products"}],"description":"Foradil P 12µg is a formoterol-based bronchodilator developed by MEDA Pharma GmbH & Co. KG, currently in Phase 2 clinical development. Formoterol is a long-acting beta-2 adrenergic agonist (LABA) used for the management of respiratory conditions including asthma and chronic obstructive pulmonary disease (COPD).","indications":{"approved":[{"status":"investigational","condition":"Asthma","patientPopulation":"Adult and paediatric patients, maintenance therapy"},{"status":"investigational","condition":"Chronic Obstructive Pulmonary Disease (COPD)","patientPopulation":"Adult patients, maintenance therapy"}]},"trialDetails":[{"nctId":"NCT01256086","phase":"PHASE2","title":"Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2010-12","conditions":"Asthma","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Foradil P 12µg","genericName":"Foradil P 12µg","companyName":"MEDA Pharma GmbH & Co. KG","companyId":"meda-pharma-gmbh-co-kg","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}